NCT04374032View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

October 7, 2020

Study Completion Date

November 3, 2020

Conditions

COVID-19 Infection

Interventions

DRUG

metenkefalin + tridecactide

ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection

DRUG

The standard of care

The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina

Trial Locations (5)

71000

Clinical Center University of Sarajevo, Sarajevo

72000

Cantonal Hospital Zenica, Zenica

72270

Hospital Travnik, Travnik

78000

University Clinical Centre of the Republic of Srpska, Banja Luka

88000

University Clinical Hospital Mostar, Mostar

All Listed Sponsors

lead

Bosnalijek D.D

INDUSTRY

NCT04374032 - Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection | Biotech Hunter | Biotech Hunter